Hayan Health Networks, Inc. has changed its corporate name to Boryung, Inc. as of 4/12/2022, and you will be forwarded to the new homepage for Boryung.com

About Us

Hayan Health Networks is a life science and healthcare investment and consulting company based in San Francisco, incorporated as the corporate venture arm of Boryung Holding.

Hayan invests in innovation to find new, effective ways to target difficult-to-treat diseases and address current medical unmet needs. By supporting early stage research and development via investments and partnerships, we hope to be a part of innovation in life science and healthcare. 




since 2019

Innovative, next generation technologies

Oncology, rare diseases, chronic diseases

Other areas with medical unmet needs

Hayan is the corporate venture arm of Boryung Holdings, and investment and management company headquartered in S. Korea. Boryung Holdings has $500M assets under management and is controlling three healthcare companies: Boryung Pharmaceutical, Boryung Biopharma and Boryung Consumer.




Peter Choi

Chief Executive Officer

  • LinkedIn

Mr. Peter Choi serves as the Chief Executive Officer at Hayan Health Networks since its founding. He is also serving a dual role as the Senior Vice President & the Head of Acquisitions & Business Development at Boryung Holdings. He focuses on legacy asset & brand acquisitions and other global business & scientific collaborations. He has over 20 years of experience in pharmaceutical industries, including business development, licensing, commercialization & market access, technology transfer, strategic partnerships, and departmental operations & management.    Read more


JP (Jung-Hwan) Shim

Chief Strategy Officer

  • LinkedIn

Mr. JP Shim currently serves as the Vice President, Chief Strategy Officer at Hayan Health Networks, while serving a dual role as the A&BD Strategy Lead at Boryung Holdings. With strong industry expertise in life science and healthcare sectors, JP has been responsible for identifying legacy brand acquisition opportunities and managing their commercial assessments. He has over 18 years of experiences in the industry, including 15 years in Pfizer APAC Region and Pfizer Korea.   Read more




Boston, USA

Investment Partners


Investment Partners


Regional Strategic Partner


Regional Strategic Partners


Boryung Pharma Group

Investment Partners

Toronto, Canada

Investment Partners

San Francisco, USA

Investment Partners




Global Life Science

PE Fund

Investment: 2019


Global Life Science

VC Fund

Investment: TBA


Korean Life Science

VC Fund

Investment: 2019

Global top private equity fund with differentiated investment models focused on assets in late stage development

Global venture capital fund with proprietary investment platform targeting emerging biotech companies 

Korean venture capital fund investing into early stage biotech companies in Korea and the US


Investment: 2020


Investment: 2020


Investment: 2020


Investment: 2020

Clinical stage biotech company developing first-in-class biologics for NASH and other fibrosis-related diseases

Biotech company developing best-in-class therapeutic antibodies with ML-based antibody discovery platform

Emerging biotech company with proprietary discovery and ML platform to identify novel targets and TCRs

Biotech company developing adoptive cell therapies with prioprietry next generation CAR-T technology